Clinical Trial Update: LHC-CIDI-5 in Hong Kong

View source ↗

Summary

A clinical trial update indicates that LHC-CIDI-5 is currently recruiting in Hong Kong for multiple psychiatric conditions, including major depressive disorder …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder
• Bipolar Disorder
• Generalized Anxiety Disorder
• Major Depressive Disorder
• Obsessive-compulsive Disorder
• Panic Disorder
• Persistent Depressive Disorder
• Post-traumatic Stress Disorder

Snippet

Sponsor: The University of Hong Kong | Conditions: Major Depressive Episode (MDE), Major Depressive Disorder (MDD) | Status: RECRUITING